Canterbury DHB
If treated early, a single dose of replacement product may be sufficient. If symptoms do not settle, consider a second dose 12 to 24 hours later. Timing of the second dose will depend on whether a short or extended half-life product is being used.
Seek specialist advice if the bleed has not settled after two doses.
Aim: To achieve a peak factor level of 30 to 40% activity.
Treatment regimen |
|
FVIII |
20 u/kg |
FIX |
30 u/kg |
In more major bleeds, use a dosing schedule with repeated doses.
Aim: To increase factor level to 30 to 40%. Repeat dosing schedule.
Treatment regimen |
||
FVIII 20 u/kg |
® 10 to 15 u/kg @ 12 hours |
® 10 u/kg @ 24 hours |
FIX 30 u/kg |
® 15 to 20 u/kg @ 12 hours |
® 15 u/kg @ 24 hours |
If symptoms persist after 24 hours, continue with the 24-hour dose regimen until symptoms settle. |
Note: In children, the plasma half-life of factor VIII and factor IX may be reduced. In these cases it may be necessary to give treatment every 8 hours.
Admit to hospital if necessary. Repeated dosing schedule.
Aim: To increase factor level to 60 to 80%, initially with dose reduction.
Treatment regimen |
|
FVIII 30 to 40 u/kg |
® 20 u/kg 12-hourly for 2 to 5 days according to severity. |
FIX 50 to 60 u/kg |
® 40 u/kg daily for 2 to 5 days according to severity. |
Dose reduction under Consultant supervision. |
Consider treatment with a continuous infusion (see above).
Consider admission to hospital for major muscle bleed.
Repeated dose schedule or continuous infusion.
Aim: To increase factor level to 80% with trough levels ³ 40% initially. Dose reduction over 7 to 10 days under Consultant supervision.
Topic Code: 5241